I intuitively agree with your fears, with a mild caveat or two; how much of my fear comes from not respecting doctors? How much comes from boo lights for social networking? Or did I have applause lights and am overcompensating for them?
Since I have no idea what your sentence means past "I fear...Google's problem" I think a lot of my agreement is bias. What might help is a better explanation of what the persistent factor is and how it would get corrupted.
Of course generally treating information as information and science as science is good, but making fast medical decisions involving lots of money and major health issues seems like a good place to introduce new information that could help lots of people. Skepticism is good but barriers to use and acceptance could be harmful.
"Google's problem" = "Search engine optimization" = people with an agenda trying to game the algorithm (so their site gets ranked higher than better ones). For example, linkspam makes "number of inbound links" a less reliable metric of site quality than it would otherwise be.
If something is known to be used as a proxy for quality and people are rewarded accordingly, then you'll end up with people trying to achieve the proxy for quality at the expense of actual quality.
I'm not sure what that has to do with the original topic, though. Are you anticipating that quacks will go on sites like this and say "You should buy my snake oil - look at all these sockpuppets that it's helped!"
When you're suffering from a life-changing illness, where do you find information about its likely progression? How do you decide among treatment options?
You don't want to rely on studies in medical journals because their conclusion-drawing methodologies are haphazard. You'll be better off getting your prognosis and treatment decisions from a social networking site: PatientsLikeMe.com.
PatientsLikeMe.com lets patients with similar illnesses compare symptoms, treatments and outcomes. As Jamie Heywood at TEDMED 2009 explains, this represents an enormous leap forward in the scope and methodology of clinical trials. I highly recommend his excellent talk, and I will paraphrase part of it below.